GBI Research, Jan 2011, Pages: 296
- Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and HepatitisC Markets”. It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global dermatology
La Merie, Sep 2008, Pages: 30
The Competitive Intelligence Report HDL Raising Therapies as of September 2008 provides a competitoranalysis in the development pipeline of novel emerging treatment modalities to raise HDL
GlobalData, Oct 2011, Pages: 25
- HepatitisC
Product Status
Product Description
Product Patent Details
Claros System - HIV
Product Status
Product Description
Product Patent Details
Claros System - Metabolic Disorders
GlobalData, July 2011, Pages: 28
analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Ramucirumab including
GlobalData, Aug 2011, Pages: 47
in the discovery, development and commercialization of small molecule drugs. The company develops products that are used in the treatment of major diseases, including HIV infection, hepatitisC virus infection
GlobalData, Sep 2011, Pages: 41
. It is developing antivirals for the treatment of chronic hepatitisC and antibacterials for the treatment of resistant bacterial infections. The company's product pipeline includes ACH-1625, a protease inhibitor
GlobalData, Nov 2010, Pages: 18
Diagnostics, Inc. Pipeline Products by Equipment Type
Advanced Diagnostics, Inc. Pipeline Products by Development Stage
Advanced Diagnostics, Inc. Pipeline Products by Therapy Area
HEPATITISC VIRUS DNA
GlobalData, May 2011, Pages: 40
viral diseases. It is engaged in the discovery and development of products to treat human viral diseases, including hepatitisC virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV
MP Advisors, Jan 2011, Pages: 391
- Clinical Data and Regulatory Analysis
- SGLT2/SGLT1 inhibitors: Preliminary Efficacy comparison
- SGLT2 inhibitors: Efficacy comparison vs. Januvia as first line therapy
- Generic Exposure Through 2014
GlobalData, Sep 2011, Pages: 21
and chronic infectious diseases including Hepatitis-C and HIV, diseases caused by drug and vaccine resistant viruses. The company's wholly owned subsidiary is Exosome Sciences, Inc. The company is headquartered
GlobalData, Oct 2011, Pages: 18
and liver regeneration; and AAV-Porphyria, a gene therapy for AIP to replenish PBGD levels.
This report is a source for data, analysis and actionable intelligence on the Digna Biotech, S.L. portfolio
GlobalData, March 2011, Pages: 19
research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key
GlobalData, Nov 2010, Pages: 19
analysis by Our team of industry experts.
Scope
- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees
GlobalData, Nov 2010, Pages: 20
Status
Product Description
Product Patent Details
Diagnostic test for gastrointestinal cancer
Product Status
Product Description
Product Patent Details
Diagnostic Test For HepatitisC
GlobalData, Sep 2011, Pages: 22
products for patients suffering with, Cardiovascular disease, Human Immunodeficiency Virus (HIV), HepatitisC, Cancer and Alzheimer's disease. It is also engaged in commercializing revenue-generating
GlobalData, May 2011, Pages: 65
Roche Diagnostics Limited - Product Pipeline Analysis
Summary
Roche Diagnostics Limited (Roche Diagnostics), a division of F. Hoffmann-La Roche Ltd. is engaged in the research, development
